Stock VTGN VISTAGEN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Sector Chart Vistagen Therapeutics, Inc.

Equities

VTGN

US92840H4002

Real-time Estimate Cboe BZX
Other stock markets
 11:27:26 2024-05-17 am EDT 		5-day change 1st Jan Change
4.565 USD +0.33% Intraday chart for Vistagen Therapeutics, Inc. +3.89% -11.67%
Apr. 25 Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue CI
Apr. 01 Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 CI
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes

Sector Bio Therapeutic Drugs

Capi. Sales growth Profitability Finances EV / Sales P/E ratio
VISTAGEN THERAPEUTICS, INC. Stock Vistagen Therapeutics, Inc.
 123M - - - -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
 114B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
 104B
BIONTECH SE Stock BioNTech SE
 22.41B -
ARGENX SE Stock argenx SE
 22.28B -
GENMAB A/S Stock Genmab A/S
 19.07B
  1. Stock Market
  2. Equities
  3. VTGN Stock
  4. Charts Vistagen Therapeutics, Inc.
  5. Sector Chart
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW